Clinical Trial: A Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTumor04 (TP04)]

U.S., Oct. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07890714) titled 'A Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTumor04 (TP04)]' on Oct. 16.

Brief Summary: This clinical trial is designed to assess the safety, tolerability, and antitumor activity of Datopotamab Deruxtecan (Dato-DXd) combined with other anticancer agents or as monotherapy in participants with solid tumors.

Study Start Date: Oct. 16

Study Type: INTERVENTIONAL

Condition: Urothelial Cancer Non-small Cell Lung Cancer

Intervention: DRUG: Dato-DXd

Dato-DXd will be administered as an IV infusion.

DRUG: Enfortumab Vedotin (EV)

EV will be administered as IV infusion.

DRUG: Pembrolizumab

Pembrolizumab will be a...